4.7 Article

Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension A Pathophysiological Continuum

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 68, Issue 4, Pages 368-378

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2016.05.047

Keywords

heart failure with preserved ejection fraction; idiopathic pulmonary arterial hypertension

Funding

  1. Actelion
  2. Bayer
  3. GlaxoSmithKline
  4. Lilly
  5. Novartis
  6. Encysive
  7. AOP Orphan
  8. Pfizer
  9. Gilead
  10. United Therapeutics
  11. Endotronix
  12. Swiss National Science Foundation
  13. Zurich Lung League
  14. Genzyme
  15. Boehringer Ingelheim

Ask authors/readers for more resources

BACKGROUND Pulmonary hypertension (PH) is hemodynamically classified as pre-capillary (as seen in idiopathic pulmonary arterial hypertension [IPAH]) or post-capillary (as seen in heart failure with preserved ejection fraction [HFpEF]). Overlaps between these conditions exist. Some patients present with risk factors for left heart disease but precapillary PH, whereas patients with HFpEF may have combined pre- and post-capillary PH. OBJECTIVES This study sought to further characterize similarities and differences among patient populations with either PH-HFpEF or IPAH. METHODS We used registry data to analyze clinical characteristics, hemodynamics, and treatment responses in patients with typical IPAH (<3 risk factors for left heart disease; n = 421), atypical IPAH (>= 3 risk factors for left heart disease; n = 139), and PH-HFpEF (n = 226) receiving PH-targeted therapy. RESULTS Compared with typical IPAH, patients with atypical IPAH and PH-HFpEF were older, had a higher body mass index, had more comorbidities, and had a lower 6-min walking distance, whereas mean pulmonary artery pressure (46.9 +/- 13.3 mm Hg vs. 43.9 +/- 10.7 mm Hg vs. 45.7 +/- 9.4 mm Hg, respectively) and cardiac index (2.3 +/- 0.8 l/min/m(2) vs. 2.2 +/- 0.8 l/min/m(2) vs. 2.2 +/- 0.7 l/min/m(2), respectively) were comparable among groups. After initiation of targeted PH therapies, all groups showed improvement in exercise capacity, functional class, and natriuretic peptides from baseline to 12 months, but treatment effects were less pronounced in patients with PH-HFpEF than typical IPAH; with atypical IPAH in between. Survival rates at 1, 3, and 5 years were almost identical for the 3 groups. CONCLUSIONS Patients with atypical IPAH share features of both typical IPAH and PH-HFpEF, suggesting that there may be a continuum between these conditions. (C) 2016 by the American College of Cardiology Foundation. Published by Elsevier.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available